Karuna Therapeutics, Inc.
KRTX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $1 | $11 | $37 | $0 |
| % Growth | -93.9% | -71.2% | – | – |
| Cost of Goods Sold | $2 | $1 | $1 | $0 |
| Gross Profit | -$1 | $10 | $36 | -$0 |
| % Margin | -160.1% | 89.5% | 98.6% | – |
| R&D Expenses | $364 | $224 | $128 | $43 |
| G&A Expenses | $131 | $76 | $53 | $28 |
| SG&A Expenses | $131 | $76 | $53 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1 | $0 | $0 |
| Operating Expenses | $495 | $300 | $181 | $72 |
| Operating Income | -$495 | -$290 | -$144 | -$72 |
| % Margin | -75,654% | -2,723.3% | -389.2% | – |
| Other Income/Exp. Net | $62 | $15 | $0 | $3 |
| Pre-Tax Income | -$433 | -$275 | -$144 | -$69 |
| Tax Expense | $1 | $1 | $0 | $0 |
| Net Income | -$434 | -$276 | -$144 | -$69 |
| % Margin | -66,311.9% | -2,597.9% | -389% | – |
| EPS | -11.73 | -8.74 | -4.94 | -2.59 |
| % Growth | -34.2% | -76.9% | -90.7% | – |
| EPS Diluted | -11.73 | -8.74 | -4.94 | -2.59 |
| Weighted Avg Shares Out | 37 | 32 | 29 | 26 |
| Weighted Avg Shares Out Dil | 37 | 32 | 29 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $61 | $14 | $1 | $3 |
| Interest Expense | $0 | $14 | $0 | $0 |
| Depreciation & Amortization | $2 | $1 | $1 | $3 |
| EBITDA | -$493 | -$260 | -$143 | -$69 |
| % Margin | -75,393.9% | -2,440.8% | -387.3% | – |